Nutraplus India Ltd.
Snapshot View

2.45 ▼0%

19 July 2021, 04:00:00 P.M.

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.nutraplusindia.com
Financial Indicators
Market Cap 8.22 Cr.
Earnings per share (EPS) -14.03 Trailing Twelve Months Ending 2020-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2020-03
Industry PE 35.17 Trailing Twelve Months Ending 2020-03
Book Value / Share 6.34 Trailing Twelve Months Ending 2020-03
Price to Book Value 0.38 Calculated using Price: 2.41
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 3.41 Cr. 34,091,086 Shares
FaceValue 5
Company Profile

Nutraplus Products India (NPIL) was incorporated as a private limited company in February 1990. The company's manufacturing unit was commissioned to make APIs and intermediates in 1995. Various products were made earlier. For a fine organic chemical manufacturing unit, the first 6 to 7 years period was crucial in a sense that proficiency in handling certain unit processes were developed. Based on such expertise, higher value and profitable products then could be taken up. In spite of liberalization of imports, reduction in import duties and indigenous competition, the company has withstood uncertainties.

The company intends to take up manufacture of an API and its intermediates by way of expansion of fixed assets. Up till now, the company adopted a stringy to carry out job working and also make selected products for a merchant exporter on fixed quantity and rate. The products made by the company hence, were exported by the merchant exporter. 

The registered office of the company is located at 7- A Vakil Villa, H F Society Road End, Jogeshwari E Mumbai, Maharashtra 400060.

Product of the company

  • N Bromo Succinimide 
  • N Methyl Nitro Guanidine
  • Chlorhexidine Gluconate  
  • 7- Chloro Quinaldine  
  • M Bromo Anisole

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
+0.41%
1 Month
-8.58%
3 Month
+1.24%
6 Month
-50.0%
1 Year
-59.17%
2 Year
-71.97%
5 Year
-95.67%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 26.78 16.73 17.18 -13.46 16.15 -11.38 0.21 3.20 -105.05
Return on Capital Employed (%) 24.89 18.92 19.24 -1.65 10.78 -2.86 4.05 7.17 -33.40
Return on Assets (%) 8.13 4.91 4.83 -4.29 5.67 -4.26 0.08 1.28 -34.00

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 13 17 20 47 63 67 67 69 22
Non Curr. Liab. 8 12 18 17 40 31 41 37 1
Curr. Liab. 23 26 37 50 63 71 63 63 89
Minority Int.
Equity & Liab. 45 54 75 114 166 169 172 170 112
Non Curr. Assets 21 28 37 36 70 87 94 100 94
Curr. Assets 23 26 38 76 95 82 78 70 18
Misc. Exp. not W/O 0 0 2 0
Total Assets 45 54 75 114 166 169 172 170 112

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 45 40 62 65 78 91 109 140 107
Other Income 0 0 0 0 0 0 0 4 0
Total Income 45 40 62 65 78 91 109 143 107
Total Expenditure -38 -32 -52 -62 -65 -93 -100 -127 -143
PBIDT 6 8 10 3 12 -2 9 17 -36
Interest -2 -2 -4 -5 -5 -5 -5 -7 -7
Depreciation -1 -1 -2 -1 -2 -2 -4 -4 -5
Taxation -1 -1 -2 2 1 2 -1 -1
Exceptional Items 0 -3 1 -2
PAT 3 2 3 -4 8 -7 0 2 -48

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 8 4 4 -16 -10 20 7 12 9
Cash Fr. Inv. -11 -9 -11 -5 -34 -19 -11 -10 -3
Cash Fr. Finan. 3 5 7 32 36 -2 4 -3 -8
Net Change 0 0 0 10 -8 -1 0 0 -1
Cash & Cash Eqvt 1 1 1 11 3 2 2 2 1

Shareholding Pattern View Details

9 Qtrs 2018-06 (%) 2018-09 (%) 2018-12 (%) 2019-03 (%) 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%)
Promoter 40.07 40.07 40.07 40.07 40.07 40.07 40.07 40.07 40.07
Public 59.93 59.93 59.93 59.93 59.93 59.93 59.93 59.93 59.93
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 24 Dec 2020
Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations 2015)
Nutraplus India Ltd has informed BSE regarding the details of Voting results of AGM under Regulation 44(3) of SEBI (LODR) Regulations 2015. Kindly Click here
Tue, 22 Dec 2020
Proceeding Of 30Th Annual General Meeting Of The Company.<BR>
Proceeding of 30th Annual General Meeting of the Company.
Fri, 04 Dec 2020
Reg. 34 (1) Annual Report
Submission of Annual Report 2019-20

Technical Scans View Details

Mon, 19 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Strongly Underperforming Benchmark index Strongly Underperforming Benchmark index
Strongly Underperforming Sectoral index Strongly Underperforming Sectoral index
Close Within 2 Year Low Zone Close Within 2 Year Low Zone

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%